Compass Pathways will report second quarter and first half 2026 financial results on August 5, with a conference call expected to update investors on its psilocybin therapy program

Compass Pathways is scheduled to announce its second quarter and first half 2026 financial results on August 5, 2026, followed by a conference call and webcast for investors. The company is a biotechnology developer focused on psilocybin-based mental health treatment, so the update sits at the intersection of public markets and psychedelic medicine commercialization. Financial calls from Compass commonly matter beyond earnings because investors watch cash position, trial progress, regulatory milestones, and timelines for its lead COMP360 program. Any management commentary can shape expectations around clinical development, competitive positioning, and the broader outlook for the psychedelic therapy sector.